Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
staphylococcus albus + neisseria catarrhalis
- Development stage
- Phase 4
- Lead developer
- Qilu Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
This drug is a combination oral tablet containing inactivated bacterial bodies of Staphylococcus albus (Staphylococcus epidermidis), Neisseria catarrhalis (now classified as Moraxella catarrhalis), and Bacillus subtilis. It is used primarily for the adjunctive treatment and prevention of chronic bronchitis and asthmatic bronchitis. The mechanism involves immunomodulation—components such as lipopolysaccharides from the bacterial cell walls can induce interferon production, activate the complement C3 pathway, stimulate reticuloendothelial system activity, enhance leukocyte phagocytosis, and improve both non-specific immunity and respiratory mucosal specific immune function. This results in increased resistance to respiratory infections[1][2][4][5][8].
- Brand names
- 白葡奈氏菌片
- Other names
- Staphylococcus and Neisseria TabletsBaipu Naishi Jun Pian气片
Beyond the preview
Go deeper on staphylococcus albus + neisseria catarrhalis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on staphylococcus albus + neisseria catarrhalis.